Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis

Autor: Gratacos, Jordi, Pontes, Caridad, Juanola, Xavier, Sanz, Jesus, Torres, Ferran, Avendano, Cristina, Vallano, Antoni, Calvo, Gonzalo, de Miguel, Eugenio, Sanmarti, Raimon, Almirall, Miriam, Aparicio, Maria, Sellas, Agusti, Vives, Roser, Albinana, Nestor, Moreno, Mireia, Clavaguera, Teresa, Carlos Torre-Alonso, Juan, Veroz, Raul, Rodriguez-Lozano, Carlos, Francisco Linares, Luis, Urruticoechea, Ana, Collantes, Eduardo, Maria Morla, Rosa, Reina, Delia, Cuende, Eduardo, Zarco, Pedro, Cruz Fernandez-Espartero, Maria, Garcia-Vicuna, Rosario, Alberto Montilla, Carlos, Villalba, Alejandro, Pascual, Dora, Campos, Cristina, Juan, Antonio, Ariza, Rafael, Diaz-Miguel, Consuelo, Maqueda, Manuel, Pilar Fernandez-Dapica, Maria, Fernandez-Prada, Manuel, Batlle, Enrique, Gonzalez-Fernandez, Carlos, Queiro, Ruben, REDES-TNF Investigators

Publikováno v: Arthritis Research & Therapy
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)

ObjectiveThe objective was to determine if dose reduction is non-inferior to full-dose TNFi to maintain low disease activity (LDA) in patients already in remission with TNFi, in axial spondyloarthritis.MethodsRandomized, parallel, non-inferiority, op

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73d6016185127229dec9f0e4ac62eee7
http://europepmc.org/articles/PMC6323809